This bill mandates the Agency for Health Care Administration to conduct or contract for a detailed fiscal impact study to assess the feasibility of implementing provisions related to discounted drug prices under the 340B Drug Pricing Program. The study will evaluate several key requirements, including mandating drug manufacturers to sell drugs to Medicaid pharmacies at the 340B discounted price for drugs on the Medicaid preferred drug list, authorizing various delivery methods for these drugs, and requiring rebates from manufacturers if the discounted price exceeds the state Medicaid negotiated price. Additionally, it stipulates that pharmacy benefits managers must pay Medicaid pharmacies the discounted price plus a professional dispensing fee for covered drugs.

The bill also outlines requirements for drug wholesalers and distributors to sell drugs at the 340B discounted price and prohibits them from altering existing pricing models that would exempt these drugs. Furthermore, it requires Medicaid pharmacies to provide covered drugs at the discounted price exclusively to Medicaid recipients. The study must be completed and submitted to the Governor and legislative leaders by January 31, 2026, and the act will take effect upon becoming law.